All things considered, it’s at least as likely to make health outcomes worse as it is to make most people healthier.

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Childhood obesity continues to be a growing problem in out country. So, should the government regulate food advertising like it did with cigarettes?

A front-of-package food label would be a great educational tool. The Trump administration should keep it.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.